Profile details
About Joshua Samuel
Josh is an associate focusing on the representation of life sciences companies on corporate, transactional, and commercial matters.
Recent work
- AbbVie on its collaboration and option agreement with Parvus Therapeutics to develop and commercialize treatments for IBD, utilizing Parvus’ proprietary NavacimTM platform technology.
- Roivant Sciences on its $7.1bn sale of Telavant to Roche.
- Novartis, as global transaction counsel, on the separation and spin-off of Sandoz, its generics and biosimilars division.
- Moderna on a strategic collaboration and license of CytomX's Probody technology for use with Moderna's mRNA therapeutics, including a $35 million upfront cash payment and up to $1.2 billion in milestones.
- Alexion, AstraZeneca Rare Disease on its acquisition of LogicBio® Therapeutics, Inc.
- Novartis in its acquisition of DTx Pharma, a biotechnology company focused on leveraging its proprietary FALCON platform to develop siRNA therapies for neuroscience indications.
Qualifications
Education
- Columbia Law School
- J.D., 2021
- Texas A&M University
- B.A., summa cum laude, 2018
Bar Admission
- Admitted to the New York State Bar